MindFrame Capture LP Revascularization Devices: Product Numbers: (a) REF 300010 (b) REF 30001...
FDA Device Recall #Z-1701-2018 — Class I — February 26, 2018
Recall Summary
| Recall Number | Z-1701-2018 |
| Classification | Class I — Serious risk |
| Date Initiated | February 26, 2018 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Micro Therapeutics Inc, Dba Ev3 Neurovascular |
| Location | Irvine, CA |
| Product Type | Devices |
| Quantity | 1,942 units |
Product Description
MindFrame Capture LP Revascularization Devices: Product Numbers: (a) REF 300010 (b) REF 300011 (c) REF 300012 (d) REF 300013 (e) REF 300014 (f) REF 300015 (g) REF 300016 (h) REF 300017 (i) REF 300018 Intended to restore blood flow by removing thrombus from a large intracranial vessel experiencing ischemic stroke within 8 hours of symptom onset.
Reason for Recall
There is a potential issue for all MindFrame Capture devices to partially detach or separate from the delivery wire.
Distribution Pattern
Worldwide Distribution
Lot / Code Information
All lot numbers: Product Number: UDI (a) REF 300010: 00843889031334, 00843889031341, 00847536020207 (b) REF 300011: 00843889031365, 00843889031372, 00847536020214 (c) REF 300012: 00843889031396, 00843889031402, 00847536020221 (d) REF 300013: 00843889031426, 00843889031433, 00847536020238 (e) REF 300014: NOT DISTRIBUTED (f) REF 300015: 00847536020122, 00847536020160 (g) REF 300016: 00847536020139, 00847536020177 (h) REF 300017: 00847536020146, 00847536020184 (i) REF 300018: 00847536020153, 00847536020191
Other Recalls from Micro Therapeutics Inc, Dba Ev3 Neuro...
| Recall # | Classification | Product | Date |
|---|---|---|---|
| Z-1527-2020 | Class I | ev3 Pipeline Flex Embolization Device. For neu... | Feb 14, 2020 |
| Z-1528-2020 | Class I | ev3 Pipeline Flex Embolization Device with Shie... | Feb 14, 2020 |
| Z-3022-2018 | Class II | ev3 TurboHawk PERPHERAL PLAQUE EXCISION SYSTEM ... | Aug 10, 2018 |
| Z-0309-2017 | Class I | Marathon Flow Directed Micro Catheter, UltraFlo... | Oct 5, 2016 |
| Z-0310-2017 | Class I | X-Celerator Hydrophilic Exchange Guidewire C... | Oct 5, 2016 |
Frequently Asked Questions
Contact your healthcare provider and the device manufacturer immediately. Check whether your specific model number and lot number are included in the recall scope. For external devices, stop using the affected product and arrange a replacement. For implanted devices, do not panic — removal is typically not required unless the risk assessment clearly indicates it. Your physician will guide you based on your individual clinical situation and the FDA's recommended actions. Report any adverse effects you may have experienced to FDA MedWatch at 1-800-FDA-1088.
Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.
Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.
What Should You Do?
Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.